BRAF and colonic neoplasm: Given that not all solid tumors with BRAF V600E mutations respond to RAF inhibition (eg, BRAF-mutant colon cancers do not benefit from vemurafenib28), these cases illustrate that recurrent LGSOC with a BRAF V600E mutation may derive clinical benefit from treatment with vemurafenib or other RAF inhibitors, arguing for routine assessment of these mutations in recurrent LGSOC.